Aclarion

Aclarion ROCE

The Return on Capital Employed (ROCE) of Aclarion (ACON) as of Oct 28, 2026 is -54.95 %. In the previous year, Return on Capital Employed (ROCE) was -665.68 % — a change of -91.75% (higher).

ROCE

-54.95 %

YoY

-91.75%

Last updated:

In 2025, Aclarion's return on capital employed (ROCE) was -54.95 %, a -91.75% increase from the -665.68 % ROCE in the previous year.

The Aclarion ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
235.86 USD
Jan 1, 2020
63.23 USD
Jan 1, 2021
78.09 USD
Jan 1, 2022
-249.94 USD
Jan 1, 2023
591.11 USD
Jan 1, 2024
-665.68 USD
Jan 1, 2025
-54.95 USD
The Aclarion ROCE history
YEARROCEYoY
-54.95 %-91.75%
-665.68 %-212.61%
591.11 %-336.50%
-249.94 %-420.08%
78.09 %+23.49%
63.23 %-73.19%
235.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aclarion Stock analysis

What does Aclarion do? Aclarion, Inc. generates revenue through its proprietary biomarker technology and signal processing software, which transforms raw Magnetic Resonance Spectroscopy (MRS) data into metabolic biomarkers for clinical use. The company's products are utilized by physicians to differentiate between painful and nonpainful lumbar spine discs, leveraging augmented intelligence in post-processing algorithms to quantify biomarker data and produce individualized ratio metrics against normative datasets. The firm targets healthcare providers focused on chronic low back pain treatment, offering solutions that optimize clinical decision-making through metabolic analysis. Aclarion's technology is centered on Magnetic Resonance Spectroscopy (MRS) and its proprietary biomarker, designed to assist physicians in determining disc-related pain in the lumbar spine. The company's signal processing software and expert system convert raw spectral MRS data into clear, actionable biomarkers, enabling tailored treatment approaches for chronic low back pain patients. By focusing exclusively on this clinical application, Aclarion serves a specialized segment of healthcare providers seeking advanced diagnostic tools for spinal conditions. Aclarion is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Aclarion's Return on Capital Employed (ROCE)

Aclarion's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Aclarion's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Aclarion's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Aclarion’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Aclarion stock

Return on Capital Employed (ROCE) of Aclarion is -54.95 % in 2025.

Return on Capital Employed (ROCE) of Aclarion changed from -665.68 % to -54.95 %, representing a -91.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Aclarion since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Aclarion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Aclarion

All Key Metrics — Aclarion